Publications
116
Citations
980
Est. group size
~29
Recurring co-author estimate
Active years
36
Publishing since 1991
Mohamed I. Elsaid conducts research in liver and gastrointestinal disease, focusing on conditions like metabolic dysfunction-associated steatotic liver disease (a fatty liver condition linked to metabolic problems), hepatitis, and liver cirrhosis, along with cancer prevention and clinical trial methodology. The work often combines large population-based or national datasets with clinical outcomes research, examining how factors like metabolic syndrome severity, socioeconomic status, and treatment approaches affect disease progression, mortality, and healthcare costs. This research spans clinical gastroenterology, oncology trial design, and health services/outcomes research.
Publication output has grown substantially over the last decade, rising from just a few papers per year before 2021 to around 20-30 per year by 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Nonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
Gastro Hep Advances · 2026
- Advancing Gastro Hep Advances: Building on Success, Looking Forward!
Gastro Hep Advances · 2026
- Challenges to and considerations of designing cancer prevention trials
JNCI Monographs · 2025
- Comparative analysis of earned value management techniques in construction projects
Scientific Reports · 2025
- Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East
Frontiers in Oncology · 2025
- When to adjust for multiplicity in cancer clinical trials
JNCI Monographs · 2025
- Editorial: Understanding How Social Determinants of Health Impact Mortality in <scp>MASLD</scp> —Insights From a National Analysis
Alimentary Pharmacology & Therapeutics · 2025
- ...The Effectiveness of Integrating Augmented Reality in Education to Stimulate Reflective Thinking among University Students..
Maǧallaẗ Kulliyyaẗ Al-Tarbiyyaẗ Bil-Manṣūraẗ · 2025
- P-112 - E-CADHERIN FRAGMENTS AS TREATMENT-GUIDE FOR NON-EROSIVE ESOPHAGEAL REFLUX DISEASE (NERD)
Gastroenterología y Hepatología · 2025
- 7785 Decrease delayed discharges in pedaitric units at king faisal specialist hospital and reasrech center qulaity improment project
2025
- Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Cirrhosis Taking Diuretics—A Promising Step Toward Fewer Serious Liver Events
JAMA Network Open · 2025
- Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with <i>MAPK</i> pathway alterations: A ComboMATCH treatment trial.
Journal of Clinical Oncology · 2024
- Enhancing Early Detection of Early Onset Colorectal Cancer: A Novel Risk Prediction Model for Colorectal Adenomas
Gastro Hep Advances · 2024
- 535 COVID-19 infection in childhood leukemia, management dilemma
2023
- Mo1526 EXCESS VISCERAL ADIPOSE TISSUE PREDICTS ALL-CAUSE MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS
Gastroenterology · 2023
- Gastroenterology×13
- Journal of Clinical Oncology×10
- The American Journal of Gastroenterology×8
- Annals of Surgical Oncology×5
- JAMA Network Open×4
- Kanika Puri
Medicine · Indiana University
- Jean P. Molleston
Medicine · Indiana University
- Eduardo Vilar‐Gómez
Medicine · Indiana University
- Howard C. Masuoka
Medicine · Indiana University
- Naga Chalasani
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile